/ /

  • linkedin
  • Increase Font
  • Sharebar

    Advancing diagnostics and detection of neovascular age-related macular degeneration

    Take-home: The ForseeHome® device gives dramatic improvements in monitoring the progression of age-related macular degeneration, allowing patients to maintain their vision.

    The damage caused by age-related macular degeneration (AMD) can develop slowly or quickly, and the early and intermediate stages often pass without symptoms. While a complete dilated eye examination will allow an ophthalmologist to detect the disease, a patient often does not notice it until their central vision is significantly deteriorated.

    Unfortunately, the outcomes of AMD treatment depend on baseline visual acuity, area and characteristics of choroidal neovascularisation (CNV)1 and, while new pharmaceutical treatment options have made great strides in terms of maintaining patients’ vision, restoration of significant vision loss is rare.

    This shifts the burden of disease management to the earliest detection of CNV, so that the best vision possible can be preserved. While there are known risk factors, there is no true predictive model for determining who will progress from dry to wet AMD and when; and the typical six-month interval between eye-care appointments could allow an alarming amount of disease progression and visual loss.

    Understanding the necessity of self-monitoring of disease, it became common in the 1960s to provide Amsler grids to patients. Although this has been the standard of care for more than half a century, limitations such as perceptual completion and lack of compliance make the overall sensitivity for detecting macular disease much less than 50%.2,3

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results